Skip to content

The effects of food intake on insulin resistance and obesity

The effects of food intake on insulin resistance and obesity - The effects of Onsen alga powder intake on insulin resistance and obesity

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000031585
Enrollment
30
Registered
2018-03-20
Start date
2017-10-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Taking in 5 capsules of test sample after breakfast or in the morning every day for 12 weeks Taking in 5 capsules of placebo sample after breakfast or in the morning every day for 12 weeks

Sponsors

SOUKEN Co., Ltd.
Lead Sponsor
Saravio Cosmetics Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Age: from 20 to 64 years old 2) BMI: 25 or more but less than 30

Exclusion criteria

Exclusion criteria: 1) Those who have more than 2.5 times of reference value of gamma-GT (gamma-GTP) 2) Those who have more than 2.5 times of reference value of AST (GOT) 3) Those who have more than 2.5 times of reference value of ALT (GPT) 4) Those who have more than 6.5 % of HbA1c value 5) Those who are taking a medicine that may influence test results. e.g. medicine that decreases the blood sugar level, etc. 6) Those who have been on a daily basis taken a health food(s) that may influence test results. e.g. health food that may decrease the blood sugar level, etc. 7) Women who are in pregnancy or may become pregnant, or are nursing 8) Those who are "Alcoholism" 9) Those who may have an allergy to the ingredient of the test sample 10) Participants in other clinical trial 11) Those who have a medical history of severe hepatic disorders, renal disorders, or cardiovascular disease 12) Those who have hepatitis or its previous history 13) Those who have severe anemia 14) Those who have hypertension 15) Those who have hyperlipidemia 16) Those who were judged inappropriate to join the study by doctor in charge

Design outcomes

Secondary

MeasureTime frame
Measurement of waist circumference, measurements of height and weight, measurement of vital sign, blood examination, findings and evaluations of a doctor, and a health state diary From the baseline to Week 12

Countries

Japan

Contacts

Public ContactKo Masuda

SOUKEN Co., Ltd Management Division

k_masuda@mail.souken-r.com+81-3-5408-1555

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026